Follow-up: Tirzepatide's shorter half-life and its one practical consequence posts 31–60

I had written a reply contradicting post #43 and deleted it. Here is what survived.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

Happy to expand any of that if it is the useful part.

Confirming post #43 from a second method, which matters more than confirming it from a second person.

Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the published schedule is not a lower bound.

Worth checking against a second source before it gets quoted onward.

Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.

SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose. That is the central and legitimate criticism of the head-to-head evidence and it is worth remembering when people quote the trial.

Scoping that to what I have actually seen rather than what I have read.

Everything in post #47 holds. The case it does not cover is the one I have.

Mass and charge states: tirzepatide is about 4813.5 Da and on an electrospray instrument you would expect to see charge states mostly in the 2+ to 4+ range, the same as semaglutide. A doubly charged species would appear at about (4813.5 + 2 × 1.008) / 2 ≈ 2408.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

Where I part company with post #48, and it is a narrow parting.

The apnoea-hypopnoea index used in SURMOUNT-OSA is an objective measurement rather than a symptom scale, which is why that trial carries more weight than its size suggests. Two parallel trials with and without positive airway pressure addressed the obvious confounder directly.

I would rather post the uncertainty than round it away.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

Not a strong opinion, just a consistent one.

Noted, and I have changed what I was going to do on the strength of it.

Confirming post #53 from a second method, which matters more than confirming it from a second person.

Gastrointestinal effects were comparable in character to the GLP-1 monoagonists across the programme. Individual reports here vary in both directions, which is what you would expect from a between-person difference rather than a between-drug one.

I had written a reply contradicting post #52 and deleted it. Here is what survived.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

The 2.5 mg starting dose is a tolerance step and not a therapeutic one. Judging efficacy at that dose is the single commonest reasoning error in this subcategory.

Written quickly, so the reasoning may be tighter than the wording.

On storage: published stability data covers the licensed formulation at its licensed concentration. A research preparation reconstituted at home in a different diluent at a different concentration is outside every one of those conditions.

I have written this out at length because the short version keeps being misread.

Thank you for taking the time. That was more work than a reply usually is.